| Name | Title | Contact Details |
|---|
Senior Living Communities | Wingate Living Step inside Wingate Living and you’ll see that we build more than beautiful residences for older adults. We’re builders of friendships and Senior Living Communities that make you feel right at home. and you’ll...
We are the leading, global mid-sized contract research organization. Our team of more than 4,200 employees working across 47 countries delivers collaborative clinical development services and solutions Designed Around You®.
Cityblock was founded in 2017 as the first tech-driven provider for communities with complex needs. We deliver better care to where it`s needed most, investing upstream in highly personalized, prevention-oriented health and social care to ultimately drive down costs and improve outcomes. Our tech enables scale by bringing together practical information, coordination, and communication for our members and our care teams. We are adamant about building a radically better member experience for people living in lower-income neighborhoods that have never been prioritized.
Parma Care Ctr is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III